Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 1, 2012Appointment Completes Company's CEO Transition Plan; Mahoney Replaces Interim CEO William H. (Hank) Kucheman
In an expected move that follows a previously announced leadership transition period, Boston Scientific Corporation (NYSE: BSX) today named Michael F....
-
Oct 31, 2012This Innovative Bioabsorbable Coating is the First to Complete Absorption Shortly after Drug Elution Ends at Three Months
Boston Scientific Corporation (NYSE: BSX) received CE Mark approval for the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System...
-
Oct 24, 2012
Boston Scientific Corporation (NYSE:BSX) has received approval to update the directions for use (DFU) labeling for PROMUS Element™ and PROMUS...
-
Oct 23, 2012PLATINUM Long Lesion Clinical Results Presented at TCT 2012 Show No Heart Attack or Stent Thrombosis at Two-Year Follow-Up
Boston Scientific Corporation (NYSE: BSX) reports clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the...
-
Oct 23, 2012Twelve-Month Data Presented at TCT 2012 Support Safety and Efficacy of Epic Stent in Iliac Stenting
Boston Scientific Corporation (NYSE: BSX) reports twelve-month clinical endpoint data from the ORION trial, which demonstrated robust safety and...
-
Oct 23, 2012Results Presented on Cost Effectiveness and Clinical Benefits for Older Patients of the WATCHMAN® Left Atrial Appendage Closure Device; Lotus™ Aortic Valve System Feasibility Trial Results Reviewed
Boston Scientific Corporation (NYSE: BSX) further demonstrated the strength of its structural heart program today at the 24th Annual Transcatheter...
-
Oct 18, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to present sponsored research at the 24th Annual Transcatheter Cardiovascular Therapeutics...
-
Oct 18, 2012
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.735 billion and adjusted earnings per share of $0.16 for the third quarter ended...
-
Oct 10, 2012REPRISE II Study Results Expected to Support CE Mark and Other Regulatory Filings
Boston Scientific (NYSE: BSX) has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus™...
-
Oct 9, 2012Victory™ guidewires are designed to facilitate crossing of resistant lesions
Boston Scientific Corporation (NYSE: BSX) has begun the United States and European launch of its Victory™ guidewire, designed to facilitate crossing...
-
Oct 8, 2012Pending Addition of Next Generation Mapping and Navigation System Would Expand Company Portfolio into Complex Electrophysiology Procedures
Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire privately-held Rhythmia Medical, Inc., a developer of...
-
Oct 8, 2012
Boston Scientific Corporation (NYSE: BSX) will webcast its third-quarter 2012 financial results conference call on Thursday, October 18th, at 8:00 a.m....
-
Oct 3, 2012These Disorders Affect Nearly 30 Million American Women; New Research Shows High Prevalence of Patients Not Understanding Their Treatment Options
Boston Scientific Corporation (NYSE: BSX) is a founding member of the Pelvic Floor Disorders (PFD) Alliance, a first-of-its-kind partnership formed to...
-
Oct 2, 2012S-ICD System is the World's First and Only Commercially Available Completely Subcutaneous Implantable Defibrillator
To view the multimedia assets associated with this release, please click:...
-
Sep 28, 2012S-ICD System is the World's First and Only Commercially Available Completely Subcutaneous Implantable Defibrillator
The U.S. Food and Drug Administration has granted Boston Scientific Corporation (NYSE: BSX) regulatory approval for its S-ICD® System, the world's...
-
Sep 28, 2012
Boston Scientific Corporation (NYSE: BSX) received CE Mark approval for use of its Vercise™ Deep Brain Stimulation (DBS) System for the treatment...
-
Sep 27, 2012Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance for the Emerge™ Percutaneous Transluminal...
-
Sep 24, 2012RELIANCE® 4-FRONT™ Lead Designed to Streamline Surgical Procedure for Treatment of Heart Failure and Sudden Cardiac Arrest
Boston Scientific Corporation (NYSE: BSX) has received regulatory approval to market the RELIANCE® 4-FRONT™ lead, its next generation implantable...
-
Sep 19, 2012Company to acquire innovative, minimally invasive technologies for the treatment of coronary chronic total occlusions
Boston Scientific Corporation (NYSE: BSX) has signed a definitive agreement to acquire BridgePoint Medical, Inc., a privately held company based in...
-
Sep 19, 2012New Bronchial Thermoplasty Procedure Codes Effective January 1, 2013
The American Medical Association (AMA) Current Procedural Terminology (CPT®1) Editorial Panel has assigned Category I CPT codes specifically for...
-
Sep 6, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2012 Morgan Stanley Global Healthcare Conference on September 12th in New...
-
Aug 28, 2012
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its PRECISION™ PLUS SPINAL CORD STIMULATOR (SCS) System in patients with...
-
Aug 27, 2012
PRECISION™ PLUS SPINAL CORD STIMULATOR System Receives CE Mark Approval for Peripheral Nerve Stimulation PARIS, August 27, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has...
-
Aug 26, 2012Newly Revised European Society of Cardiology Guidelines Include LAA Closure Devices
European regulators have approved an expanded indication for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN® Left Atrial Appendage (LAA)...
-
Jul 27, 2012First European Implants of INGENIO™ MRI Pacemaker with New Image Ready™ Technology Performed This Week
PARIS (July 27, 2012) -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its INGENIO™ and ADVANTIO™ pacemakers in patients in need of a magnetic resonance...
-
Jul 26, 2012
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.828 billion and adjusted earnings per share of $0.17 for the second quarter ended June...
-
Jul 18, 2012Studies Show Innovative Devices Deliver Significant Pain Relief and Reduce Lead Migration in Patients with Chronic Pain
Boston Scientific Corporation (NYSE: BSX) has presented results of two studies evaluating the Infinion™ 16 Percutaneous Lead, the world's first and...
-
Jul 12, 2012
Boston Scientific Corporation (NYSE: BSX) will webcast its second-quarter 2012 financial results conference call on Thursday, July 26, at 8:00 a.m....
-
Jul 2, 2012Milestone Marks Next Step Toward FDA Submission for Stroke Reduction Device for Patients with Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the PREVAIL confirmatory study, designed to gain U.S. Food and Drug...
-
Jun 26, 2012
Boston Scientific Corporation (NYSE: BSX) welcomes final passage today by the United States Senate of "The Food and Drug Administration Safety and...
-
Jun 14, 2012
Natick, MA (June 14, 2012) –Warren Wang has been appointed Vice President and Managing Director of Boston Scientific Corporation’s (NYSE:BSX) operations in China. Mr. Wang is responsible for...
-
Jun 14, 2012Boston Scientific Announces First Patient Active with LATITUDE™ NXT Remote Patient Management SystemNext-generation wireless remote patient management system enabled for INGENIO(TM) family of pacemakers is now in use in Europe
NATICK, Mass. and PARIS (June 14, 2012) – Boston Scientific Corporation (NYSE: BSX) has initiated use of the LATITUDE NXT Remote Patient Management System with patients in Europe. Dr. Roberto...
-
Jun 8, 2012Adds First and Only Commercially Available Subcutaneous ICD Technology that Offers New Life-Saving Therapy Option to Patients at Risk of Sudden Cardiac Arrest
Boston Scientific Corporation (NYSE: BSX) has closed its acquisition of Cameron Health, Inc. of San Clemente, California, and, as a result, added to its...
-
Jun 7, 2012Medical Device Tax Would Stifle Innovation
Boston Scientific (NYSE: BSX) applauds the passage today by the House of Representatives of HR 436, the "Protect Medical Innovation Act." This bill...
-
Jun 6, 2012Event to be webcast live and will include detailed review of Bronchial Thermoplasty opportunity
Boston Scientific Corporation (NYSE: BSX) will hold a review of its Endoscopy business, including its Bronchial Thermoplasty opportunity, on Monday,...
-
Jun 4, 2012PROMUS Element Plus Stent System Offers Physicians the Broadest Array of Everolimus Drug-eluting Stent lengths and diameters in the U.S.
The U.S. Food and Drug Administration (FDA) has provided Boston Scientific Corporation (NYSE: BSX) regulatory approval of 32 mm and 38 mm lengths for...
-
May 31, 2012Devices Projected to Have Nearly Twice the Longevity of Comparable Products
The U.S. Food and Drug Administration (FDA) has approved revised product labeling for the Boston Scientific Corporation (NYSE: BSX) INCEPTA™,...
-
May 29, 2012Indication Provides New Therapeutic Option for Extraction of Difficult-to-Manage Biliary Stones
Boston Scientific Corporation (NYSE: BSX) announces the U.S. Food and Drug Administration has cleared an expanded use indication for the CRE™...
-
May 18, 2012
Boston Scientific Corporation (NYSE: BSX) announces that seven abstracts and additional clinical data analyses will be presented at Digestive Disease Week®
-
May 18, 2012Two-year Clinical Data Demonstrate Low Adverse Event Rates, Including No Myocardial Infarction or Stent Thrombosis, for the Boston Scientific 2.25 mm PROMUS Element Platinum Chromium Stent
Boston Scientific Corporation (NYSE: BSX) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and...
-
May 17, 2012New Self-Expanding Nitinol Stent Offers Balance of Flexibility and Radial Strength for Enhanced Performance in Iliac Stenting Procedures
Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration approval and market launch of the Epic™ Vascular Self-Expanding...
-
May 15, 2012Follow-up Data from EVOLVE Trial Presented at EuroPCR; Trial is Evaluating Next-Generation Everolimus-Eluting Platinum Chromium Coronary Stent with Ultra-Thin Bioabsorbable Abluminal Polymer
Boston Scientific Corporation (NYSE: BSX) announces that the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary...
-
May 15, 2012Results of REPRISE I Study Suggest Device Minimizes Aortic Regurgitation
Boston Scientific Corporation (NYSE: BSX) announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus™...
-
May 14, 2012Innovative Stent Designed to Treat Peripheral Vascular Lesions for Stenoses in Arteries above the Knee
Boston Scientific Corporation (NYSE: BSX) announces CE Mark and European market launch of the Innova™ Self-Expanding Bare-Metal Stent System, which...
-
May 14, 2012Collaboration expected to improve access to imaging data used to treat patients
Boston Scientific Corporation (NYSE: BSX) and Royal Philips Electronics (NYSE: PHG, AEX: PHI) announced a collaboration enabling Philips to...
-
May 11, 2012Results Presented at Heart Rhythm Society from ASA Plavix Study Evaluating Boston Scientific Left Atrial Appendage Closure Device
Boston Scientific Corporation (NYSE: BSX) announces results from the ASA Plavix (ASAP) Study, which studied the WATCHMAN® Left Atrial...
-
May 10, 2012Clinical Presentations to Include 12-month Outcomes Data from EVOLVE Trial and Results of the REPRISE I Trial
Boston Scientific Corporation (NYSE: BSX) announces its schedule of major events and sponsored clinical research at the annual EuroPCR Scientific...
-
May 7, 2012Advanced Pacemaker Platform Designed to Treat Chronotropic Incompetence, which Affects up to 42 Percent of Pacemaker Patients
Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval and market launch of its INGENIO™ and ADVANTIO™...
-
May 3, 2012
Boston Scientific Corporation (NYSE: BSX) announces its schedule of major events and sponsored research at Heart Rhythm 2012, the Heart Rhythm Society's...
-
Apr 26, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2012 Deutsche Bank Healthcare Conference on May 8 in Boston. Hank...